Current Research Studies
AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
AALL1621
What is the goal of the study?
AALL1621 is a group-wide single-arm phase 2 study to evaluate the toxicity profile and preliminary efficacy of inotuzumab ozogamicin (InO) in pediatric patients with CD22-positive B-lymphoblastic leukemia (B-ALL) that is refractory or in second or greater relapse. InO is an antibody-drug conjugate composed of a humanized IgG subtype 4 monoclonal CD22-targeted antibody linked to calicheamicin, a potent anti-tumor antibiotic. InO demonstrated exceptional activity in relapsed or refractory B-ALL in adults.
Who can participate in the study?
Please contact the study team listed below to learn more.